Asset: Novel gastric mucosa-protective recombinant polypeptide
Development Stage: IND enabling stage
Indication: Chronic gastritis and chronic atrophic gastritis
Key Asset Highlights:
（1）Dual-functional pharmacological profile featuring potent inhibition of gastric acid secretion and significant promotion of gastric mucosal repair, targeting core pathological mechanisms of chronic gastric lesions.
（2）Effectively suppresses excessive gastric acid release and reduces persistent mucosal irritation, relieving inflammatory erosion and mitigating progressive damage to gastric mucosal tissues.
（3）Accelerates the regeneration and reconstruction of damaged gastric mucosa, reversing mucosal atrophy and pathological deterioration associated with chronic atrophic gastritis.
（4）Exhibits distinct differentiated advantages over conventional acid-suppressive drugs, achieving both symptomatic relief and mucosal tissue repair to address the root causes of chronic gastritis.
（5）Demonstrates favorable biocompatibility and a broad safety window, supporting long-term intermittent administration for chronic gastric disease intervention and rehabilitation.
（6）Backed by a comprehensive intellectual property portfolio, securing stable and exclusive global development and commercialization rights for chronic gastritis treatment.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
